Company: BSX
Filing Date: 2025-02-18
Form Type: 10-K
Source: 0000885725-25-000011
Chunk: 190

Company: BOSTON SCIENTIFIC CORP
Filing Date: 2025-02-18
Form: 10-K
Item: Item 8
Chunk 190
---
 Net sales of reportable segments less Segment expenses.(3)    In 2022, amounts reflect sales reserves established for Italian government payback provisions, which are being disputed in the Italian court system. These amounts were not allocated to our reportable segments or considered by our CODM for resource allocation and decision-making purposes. Year Ended December 31,Depreciation expense (in millions)202420232022MedSurg$110 $103 $88 Cardiovascular302 263 245 Consolidated depreciation expense$412 $367 $333 As of December 31,Total assets (in millions)20242023MedSurg$3,093 $2,888 Cardiovascular7,084 5,988 Total assets of reportable segments10,177 8,876 Goodwill17,089 14,387 Other intangible assets, net6,684 6,003 All other corporate assets5,446 5,869  $39,395 $35,136 

116

As of December 31,Long-lived assets (in millions)20242023U.S.$1,461 $1,300 Ireland631 598 Costa Rica530 373 Other countries672 587 Property, plant and equipment, net3,294 2,859 Goodwill17,089 14,387 Other intangible assets, net6,684 6,003 Operating lease right-of-use assets in Other long-term assets449 439  $27,516 $23,688 

117

NOTE N – REVENUEWe generate revenue primarily from the sale of single-use medical devices and present revenue net of sales taxes within our consolidated statements of operations. Our business structure is organized into five operating segments. The following tables disaggregate our revenue from contracts with customers by business unit and geographic region (in millions). Generally, we allocate revenue from contracts with customers to geographic regions based on the location where the sale originated. Year Ended December 31,202420232022BusinessesU.S.Int'lTotalU.S.Int'lTotalU.S.Int'lTotalEndoscopy$1,651 $1,036 $2,687 $1,511 $970 $2,482 1,341 $880 $2,221 Urology1,557 643 2,200 1,369 595 1,964